Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696291 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
A Phase 1 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02696291: Clinical Trial Phase 1 study, sponsored by Emergent BioSolutions.
NCT02696291 is a Phase 1 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02696291, a Phase 1 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
Primary Outcome
The incidence of TEAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple TEAEs are counted only once.
Interventions
- DRUG UV-4B 30 mg oral solution
- DRUG UV-4B 75 mg oral solution
- DRUG UV-4B 150 mg oral solution
- DRUG UV-4B X mg (dose to be determined) oral solution
- DRUG UV-4B Y mg (dose to be determined) oral solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2017-03-02 |
| Phase | Phase 1 |
Why NCT02696291 stopped before completion
NCT02696291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which UV-4B 30 mg oral solution is the first listed.
NCT02696291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02696291 about?
NCT02696291 is a clinical study titled "Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects". The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
What is the current status of trial NCT02696291?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-05-27. Estimated completion is 2017-03-02.
What interventions are being tested in trial NCT02696291?
The interventions under investigation include: UV-4B 30 mg oral solution (DRUG), UV-4B 75 mg oral solution (DRUG), UV-4B 150 mg oral solution (DRUG), UV-4B X mg (dose to be determined) oral solution (DRUG), UV-4B Y mg (dose to be determined) oral solution (DRUG).
Who is sponsoring clinical trial NCT02696291?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02696291's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI